Xeloda Experiences Double Digit Sales Growth
Xeloda (capecitabine), an oral medicine that simplifies the treatment of colorectal, breast and stomach cancer, continued its double-digit sales growth globally. Growth in Japan was particularly strong (62%), with double-digit gains also recorded in North America and Europe. Sales growth is being driven by new and expanded indications approved in 2007 and 2008, notably in stomach and colorectal cancer, and by greater uptake in the treatment of breast cancer.
In February the EU authorities approved Xeloda for the treatment of metastatic colorectal cancer in combination with any chemotherapy in all lines of treatment, with or without Avastin.